Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025" hreflang="en">Fierce Biotech Layoff Tracker 2025: Applied Tx lays off 46% of staff; Ensoma makes cuts</a>
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
<a href="https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation" hreflang="en">In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation</a>
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in...
<a href="https://www.fiercebiotech.com/biotech/gilead-hatches-400m-biobucks-deal-swedish-biotechs-trex1-cancer-program" hreflang="en">Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program</a>
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in bio...
In the clinic for Nov. 25, 2025
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Jyong Biotech, Lynk, Innovent.
Biogen strikes deal with Versant-backed biotech to expand immune portfolio
Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."
Roche inks $200M pact for Freenome's cancer screening blood test - Fierce Biotech
Roche inks $200M pact for Freenome's cancer screening blood test Fierce Biotech
A brain biotech’s top drug fails against MS
Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for a drug that’s also piqued Johnson & Johnson...
Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial - Fierce Biotech
Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial Fierce Biotech
Therapeutics Come Alive: An Interview with PharmaBiome
PharmaBiome, a Zurich-based biotechnology company, is pioneering the development of living microbiome therapies to address gut health issues. Utilizing their NicheMap™...
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed - Fierce Biotech
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed Fierce Biotech
Illumina shares rise as China set to lift sequencer export ban - Fierce Biotech
Illumina shares rise as China set to lift sequencer export ban Fierce Biotech
Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain - Fierce Biotech
Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain Fierce Biotech
Illumina sales flat in Q3 amid China headwinds as CEO remains 'in dialogue' with agencies - Fierce Biotech
Illumina sales flat in Q3 amid China headwinds as CEO remains 'in dialogue' with agencies Fierce Biotech
Thermo Fisher adds clinical trial tech outfit Clario to goodie bag in $9B deal - Fierce Biotech
Thermo Fisher adds clinical trial tech outfit Clario to goodie bag in $9B deal Fierce Biotech
Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific - Fierce Biotech
Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific Fierce Biotech
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights - Business Wire
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights Business Wire
Lonza to buy rapid microbial testing firm Redberry SAS - Fierce Biotech
Lonza to buy rapid microbial testing firm Redberry SAS Fierce Biotech
Roche axes 4 Chugai solid tumor assets in early-phase clear-out - Fierce Biotech
BIOTECH Roche axes 4 Chugai solid tumor assets in early-phase clear-out By Nick Paul Taylor Oct 23, 2025 4:53am Roche Chugai solid tumor endometriosis Roche has dropped...
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page Thermo Fisher Core Tools & Instruments
Track Danaher Core Tools & Instruments
Track Agilent Core Tools & Instruments
Track Merck KGaA Core Tools & Instruments
Track Illumina Core Tools & Instruments
Track Waters Core Tools & Instruments
Track Bruker Core Tools & Instruments
Track Sartorius Core Tools & Instruments
Track Mettler Toledo Core Tools & Instruments
Track PerkinElmer (Revvity) Core Tools & Instruments
Track Bio-Rad Core Tools & Instruments
Track Carl Zeiss Core Tools & Instruments
Track Leica Microsystems Core Tools & Instruments
Track Nikon Core Tools & Instruments
Track Eppendorf Core Tools & Instruments
Track Corning Core Tools & Instruments
Track BD (Becton Dickinson) Core Tools & Instruments
Track Beckman Coulter Core Tools & Instruments
Track Qiagen Core Tools & Instruments
Track Abcam Core Tools & Instruments
Track MGI Tech (华大智造) Core Tools & Instruments
Track Haier Biomedical Core Tools & Instruments
Track Lonza Outsourcing Services (CRO / CDMO)
Track WuXi AppTec (药明康德) Outsourcing Services (CRO / CDMO)
Track WuXi Biologics Outsourcing Services (CRO / CDMO)
Track Charles River Outsourcing Services (CRO / CDMO)
Track Catalent Outsourcing Services (CRO / CDMO)
Track Samsung Biologics Outsourcing Services (CRO / CDMO)
Track IQVIA Outsourcing Services (CRO / CDMO)
Track LabCorp Outsourcing Services (CRO / CDMO)
Track Eurofins Outsourcing Services (CRO / CDMO)
Track Pharmaron (康龙化成) Outsourcing Services (CRO / CDMO)
Track Pfizer Pharma, Biotech & AI
Track Roche